These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24258145)

  • 21. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 23. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 24. Biopharmaceutical benchmarks--2003.
    Walsh G
    Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
    [No Abstract]   [Full Text] [Related]  

  • 25. Market watch: upcoming market catalysts in Q3 2012.
    Jeng R
    Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
    [No Abstract]   [Full Text] [Related]  

  • 26. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 27. Lifecycle management for recombinant protein production using mammalian cell culture technology.
    Moran E; Gammell P
    Adv Biochem Eng Biotechnol; 2014; 139():245-56. PubMed ID: 24196316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biopharmaceutical benchmarks 2010.
    Walsh G
    Nat Biotechnol; 2010 Sep; 28(9):917-24. PubMed ID: 20829826
    [No Abstract]   [Full Text] [Related]  

  • 30. The year's new drugs and biologics--2007.
    Graul AI; Prous JR; Barrionuevo M; Bozzo J; Castaner R; Cruces E; Revel L; Rosa E; Serradell N; Sorbera LA
    Drug News Perspect; 2008; 21(1):7-35. PubMed ID: 18301807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 32. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
    Paradise J
    Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of 'Omics technology to rationally improve industrial mammalian cell line performance.
    Lewis AM; Abu-Absi NR; Borys MC; Li ZJ
    Biotechnol Bioeng; 2016 Jan; 113(1):26-38. PubMed ID: 26059229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopharmaceuticals: recent approvals and likely directions.
    Walsh G
    Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market.
    Hashitera Y; Saotome C; Yamamoto H
    Drug Discov Today; 2013 Nov; 18(21-22):1109-16. PubMed ID: 23856327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative and economic potential of mammalian cell culture.
    Werner RG
    Arzneimittelforschung; 1998 Apr; 48(4):423-6. PubMed ID: 9608886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.
    Gagnon MA; Lexchin J
    PLoS Med; 2008 Jan; 5(1):e1. PubMed ID: 18177202
    [No Abstract]   [Full Text] [Related]  

  • 40. The year's new drugs and biologics--2006.
    Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR
    Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.